MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

MDT

97.62

+2.1%↑

VEEV

295.33

-1.66%↓

A

141.88

+2.34%↑

HQY

88.54

-1.25%↓

PHR.US

23.21

+1.66%↑

Search

Recursion Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

5.49 -0.36

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.34

Max

5.69

Belangrijke statistieken

By Trading Economics

Inkomsten

31M

-172M

Verkoop

4.4M

19M

Winstmarge

-899.843

Werknemers

800

EBITDA

44M

-148M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+7.79% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-405M

2.1B

Vorige openingsprijs

5.85

Vorige sluitingsprijs

5.49

Nieuwssentiment

By Acuity

50%

50%

152 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 okt 2025, 14:47 UTC

Belangrijke Marktbewegers

Esperion Therapeutics Shares Rise After Blocking Generic Version of Cholesterol Drug

3 okt 2025, 14:25 UTC

Belangrijke Marktbewegers

Shopify Shares Rise as TD Cowen Raises Price Target

3 okt 2025, 13:20 UTC

Acquisities, Fusies, Overnames

Anglo American Initiates Arbitration Proceedings After Peabody Deal Falls Through

3 okt 2025, 12:40 UTC

Belangrijke Marktbewegers

Alto Neuroscience Shares Rise After Getting FDA Fast-Track Designation

3 okt 2025, 22:02 UTC

Acquisities, Fusies, Overnames

First National Financial Gets Ontario Court Approval for Sale to Birch Hill Equity and Brookfield

3 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 okt 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

3 okt 2025, 19:56 UTC

Marktinformatie

Treasury Yields Have Weekly Loss as Key Statistics Go Unseen -- Market Talk

3 okt 2025, 19:52 UTC

Acquisities, Fusies, Overnames

This Mini-Berkshire Insurer Looks Cheap After Sale Of California Unit At High Price -- Barrons.com

3 okt 2025, 19:21 UTC

Marktinformatie

Crude Prices End Week Lower Ahead of OPEC Meeting -- Market Talk

3 okt 2025, 19:05 UTC

Marktinformatie

Natural-Gas Futures Face Mild Temperatures -- Market Talk

3 okt 2025, 19:04 UTC

Acquisities, Fusies, Overnames

BlackRock Group Hunts a $20 billion Deal to Get In on the AI Boom -- WSJ

3 okt 2025, 18:22 UTC

Marktinformatie

Bank of Canada Tentative About More Rate Cuts Due to Upside CPI Risks -- Market Talk

3 okt 2025, 17:15 UTC

Marktinformatie

U.S. Oil Rig Count Decreased Last Week -- Market Talk

3 okt 2025, 16:26 UTC

Marktinformatie

Long-Term Treasury Yields Expected to Shrug Off Fed Cut -- Market Talk

3 okt 2025, 16:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

3 okt 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

3 okt 2025, 16:16 UTC

Marktinformatie

Alaska Air, American Airlines Expected to Post Disappointing 3Q Results -- Market Talk

3 okt 2025, 16:02 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

3 okt 2025, 16:02 UTC

Marktinformatie

Airline Industry Bifurcation Likely to Define 3Q Earnings -- Market Talk

3 okt 2025, 15:17 UTC

Acquisities, Fusies, Overnames

Tech Buyouts Have Heated Up. These 8 Companies Could Be Next. -- Barrons.com

3 okt 2025, 14:56 UTC

Marktinformatie

European Credit Spreads Could Tighten as New Supply Stays Low -- Market Talk

3 okt 2025, 14:10 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 okt 2025, 14:10 UTC

Marktinformatie

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

3 okt 2025, 13:34 UTC

Marktinformatie

Natural Gas Futures Down Amid High Supply, Mild Demand -- Market Talk

3 okt 2025, 13:29 UTC

Marktinformatie

Crude Prices Rise Slightly Ahead of OPEC+ Meeting -- Market Talk

3 okt 2025, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

3 okt 2025, 13:14 UTC

Marktinformatie

Brazilian Companies Face Higher Financing Costs, Fitch Says -- Market Talk

3 okt 2025, 13:10 UTC

Marktinformatie

Bitcoin Looks Ripe For Fresh Record High -- Market Talk

3 okt 2025, 12:52 UTC

Marktinformatie

Ferrari Results Secondary to Investor Day -- Market Talk

Peer Vergelijking

Prijswijziging

Recursion Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

7.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.95 USD  7.79%

Hoogste 8 USD

Laagste 3 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Recursion Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

5 ratings

1

Buy

4

Hold

0

Sell

Technische score

By Trading Central

4.15 / 4.75Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

152 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat